Literature DB >> 30257898

Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.

Helio S Sader1, Paul R Rhomberg2, Timothy B Doyle2, Robert K Flamm2, Rodrigo E Mendes2.   

Abstract

We assessed ceftaroline disk diffusion breakpoints for Staphylococcus aureus when applying revised Clinical and Laboratory Standards Institute (CLSI) ceftaroline MIC breakpoints. Disk-MIC correlation was evaluated by testing a challenge collection (n = 158) of methicillin-resistant S. aureus (MRSA) isolates composed of 106 randomly selected isolates plus 52 isolates with decreased susceptibility to ceftaroline (MIC, 1 to 16 μg/ml). Disk diffusion was performed with 30-μg disks and Mueller-Hinton agar from 2 manufacturers each. Revised CLSI susceptible (S)/susceptible dose-dependent (SDD)/resistant (R) MIC breakpoints of ≤1/2 to 4/≥8 μg/ml were applied. The disk breakpoints that provided the lowest error rates were CLSI S/R breakpoints of ≥25 mm/≤19 mm, with no very major (VM) or major (Ma) errors and with minor (Mi) error rates of 0.0% for ≥2 doubling dilutions above the I or SDD (≥I + 2), 22.1% for I or SDD plus or minus 1 doubling dilution (I ± 1), and 2.3% for ≤2 doubling dilutions below the I or SDD ≤I - 2 (overall Mi error rate, 16.5%). No mutation in the penicillin-binding protein 2a (PBP2a) was observed in 5 of 15 isolates with a ceftaroline MIC of 2 μg/ml; 3 of 11 isolates with a ceftaroline MIC of 1 μg/ml exhibited mutations in the penicillin-binding domain (PBD; 1 isolate) or in the non-PBD (2 isolates). All isolates except 1, with a ceftaroline MIC of ≥4 μg/ml, showed ≥1 mutation in the PBD and/or non-PBD. In summary, results from the disk diffusion method showed a good correlation with those from the reference broth microdilution method. Our results also showed that the ceftaroline MIC distribution of isolates with no mutations in the PBP2a goes up to 4 μg/ml, and reference broth microdilution and disk diffusion methods do not properly separate wild-type from non-wild-type isolates.
Copyright © 2018 Sader et al.

Entities:  

Keywords:  MRSA; ceftaroline; disk diffusion

Mesh:

Substances:

Year:  2018        PMID: 30257898      PMCID: PMC6258841          DOI: 10.1128/JCM.00777-18

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

Review 1.  Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy.

Authors:  Kyra Chua; Frederic Laurent; Geoffrey Coombs; M Lindsay Grayson; Benjamin P Howden
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

Review 2.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

3.  Penicillin-binding protein 4 overproduction increases beta-lactam resistance in Staphylococcus aureus.

Authors:  U U Henze; B Berger-Bächi
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic.

Authors:  Karen L Nielsen; Thomas M Pedersen; Klas I Udekwu; Andreas Petersen; Robert L Skov; Lars H Hansen; Diarmaid Hughes; Niels Frimodt-Møller
Journal:  J Antimicrob Chemother       Date:  2012-02-29       Impact factor: 5.790

5.  Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.

Authors:  Sushmita D Lahiri; Richard A Alm
Journal:  J Antimicrob Chemother       Date:  2016-08-05       Impact factor: 5.790

6.  Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.

Authors:  Mariana Castanheira; Helio S Sader; David J Farrell; Rodrigo E Mendes; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

7.  Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.

Authors:  R M Humphries; J A Hindler
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

8.  Evolution of MRSA during hospital transmission and intercontinental spread.

Authors:  Simon R Harris; Edward J Feil; Matthew T G Holden; Michael A Quail; Emma K Nickerson; Narisara Chantratita; Susana Gardete; Ana Tavares; Nick Day; Jodi A Lindsay; Jonathan D Edgeworth; Hermínia de Lencastre; Julian Parkhill; Sharon J Peacock; Stephen D Bentley
Journal:  Science       Date:  2010-01-22       Impact factor: 47.728

9.  Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus.

Authors:  D Ashley Robinson; Mark C Enright
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  A Prospective Cohort Multicenter Study of Molecular Epidemiology and Phylogenomics of Staphylococcus aureus Bacteremia in Nine Latin American Countries.

Authors:  Cesar A Arias; Jinnethe Reyes; Lina Paola Carvajal; Sandra Rincon; Lorena Diaz; Diana Panesso; Gabriel Ibarra; Rafael Rios; Jose M Munita; Mauro J Salles; Carlos Alvarez-Moreno; Jaime Labarca; Coralith Garcia; Carlos M Luna; Carlos Mejia-Villatoro; Jeannete Zurita; Manuel Guzman-Blanco; Eduardo Rodriguez-Noriega; Apurva Narechania; Laura J Rojas; Paul J Planet; George M Weinstock; Eduardo Gotuzzo; Carlos Seas
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

View more
  2 in total

Review 1.  One Size Fits All? Application of Susceptible-Dose-Dependent Breakpoints to Pediatric Patients and Laboratory Reporting.

Authors:  Lindsey E Nielsen; Jeanne B Forrester; Jennifer Ellis Girotto; Aimee M Dassner; Romney Humphries
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

2.  Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.

Authors:  Maria Celeste Varela; Melanie Roch; Agustina Taglialegna; Scott W Long; Matthew Ojeda Saavedra; Warren E Rose; James J Davis; Lucas R Hoffman; Rafael E Hernandez; Roberto R Rosato; Adriana E Rosato
Journal:  Commun Biol       Date:  2020-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.